AIMS/HYPOTHESIS: A role for increased activity of the innate immune system in the pathogenesis of insulin resistance is supported by a number of studies. The current study assessed the potential role of the lipopolysaccharide receptor known as Toll-like receptor-4 (TLR-4), a component of the innate immune system, in mediating lipid-induced insulin resistance in skeletal muscle. METHODS: The effects of TLR-4 inhibition/deletion on lipid-induced insulin resistance was determined in skeletal muscle of TLR-4 null mice in vivo and in rat L6 myotubes in vitro. RESULTS: In mice, acute hyperlipidaemia induced skeletal muscle insulin resistance, but a deletion of TLR-4 conferred significant protection against these effects. In L6 myotubes, inhibition of TLR-4 activity substantially reduced the capacity of the saturated fatty acid palmitate to induce insulin resistance. Importantly, palmitate activated the nuclear factor kappaB (NFkappaB) pathway in L6 myotubes and mouse skeletal muscle, and these effects were blocked by inhibition of TLR-4 in L6 myotubes and absence of TLR-4 in skeletal muscle. Furthermore, inhibition of the NFkappaB pathway downstream of TLR-4 in L6 myotubes also protected against the induction of insulin resistance by palmitate. CONCLUSIONS/ INTERPRETATION: Inhibition or absence of TLR-4 confers protection against the detrimental effects of lipids on skeletal muscle insulin action, and these effects are associated with a prevention of the activation of the NFkappaB pathway by lipids. Importantly, inhibition of the NFkappaB pathway in myotubes downstream of TLR-4 also protects against lipid-induced insulin resistance, suggesting a mechanism by which reduced TLR-4 activity confers beneficial effects on insulin action.
AIMS/HYPOTHESIS: A role for increased activity of the innate immune system in the pathogenesis of insulin resistance is supported by a number of studies. The current study assessed the potential role of the lipopolysaccharide receptor known as Toll-like receptor-4 (TLR-4), a component of the innate immune system, in mediating lipid-induced insulin resistance in skeletal muscle. METHODS: The effects of TLR-4 inhibition/deletion on lipid-induced insulin resistance was determined in skeletal muscle of TLR-4 null mice in vivo and in rat L6 myotubes in vitro. RESULTS: In mice, acute hyperlipidaemia induced skeletal muscle insulin resistance, but a deletion of TLR-4 conferred significant protection against these effects. In L6 myotubes, inhibition of TLR-4 activity substantially reduced the capacity of the saturated fatty acid palmitate to induce insulin resistance. Importantly, palmitate activated the nuclear factor kappaB (NFkappaB) pathway in L6 myotubes and mouse skeletal muscle, and these effects were blocked by inhibition of TLR-4 in L6 myotubes and absence of TLR-4 in skeletal muscle. Furthermore, inhibition of the NFkappaB pathway downstream of TLR-4 in L6 myotubes also protected against the induction of insulin resistance by palmitate. CONCLUSIONS/ INTERPRETATION: Inhibition or absence of TLR-4 confers protection against the detrimental effects of lipids on skeletal muscle insulin action, and these effects are associated with a prevention of the activation of the NFkappaB pathway by lipids. Importantly, inhibition of the NFkappaB pathway in myotubes downstream of TLR-4 also protects against lipid-induced insulin resistance, suggesting a mechanism by which reduced TLR-4 activity confers beneficial effects on insulin action.
Authors: Gina B Di Gregorio; Aiwei Yao-Borengasser; Neda Rasouli; Vijayalakshmi Varma; Tong Lu; Leslie M Miles; Gouri Ranganathan; Charlotte A Peterson; Robert E McGehee; Philip A Kern Journal: Diabetes Date: 2005-08 Impact factor: 9.461
Authors: Melek C Arkan; Andrea L Hevener; Florian R Greten; Shin Maeda; Zhi-Wei Li; Jeffrey M Long; Anthony Wynshaw-Boris; Giuseppe Poli; Jerrold Olefsky; Michael Karin Journal: Nat Med Date: 2005-01-30 Impact factor: 53.440
Authors: O P Bachmann; D B Dahl; K Brechtel; J Machann; M Haap; T Maier; M Loviscach; M Stumvoll; C D Claussen; F Schick; H U Häring; S Jacob Journal: Diabetes Date: 2001-11 Impact factor: 9.461
Authors: A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler Journal: Science Date: 1998-12-11 Impact factor: 47.728
Authors: Madlyn I Frisard; Ryan P McMillan; Julie Marchand; Kristin A Wahlberg; Yaru Wu; Kevin A Voelker; Leonie Heilbronn; Kimberly Haynie; Brendan Muoio; Liwu Li; Matthew W Hulver Journal: Am J Physiol Endocrinol Metab Date: 2010-02-23 Impact factor: 4.310
Authors: Sangeeta Ghosh; Raweewan Lertwattanarak; Jose de Jesus Garduño; Joaquin Joya Galeana; Jinqi Li; Frank Zamarripa; Jack L Lancaster; Sumathy Mohan; Sophie Hussey; Nicolas Musi Journal: J Gerontol A Biol Sci Med Sci Date: 2014-05-20 Impact factor: 6.053
Authors: Anantha Metlakunta; Wan Huang; Maja Stefanovic-Racic; Nikolaos Dedousis; Ian Sipula; Robert M O'Doherty Journal: Am J Physiol Endocrinol Metab Date: 2016-11-08 Impact factor: 4.310
Authors: Peter Weyrich; Harald Staiger; Alena Stančáková; Fausto Machicao; Jürgen Machann; Fritz Schick; Norbert Stefan; Johanna Kuusisto; Markku Laakso; Silke Schäfer; Andreas Fritsche; Hans-Ulrich Häring Journal: PLoS One Date: 2010-11-15 Impact factor: 3.240
Authors: Wan Huang; Anantha Metlakunta; Nikolaos Dedousis; Pili Zhang; Ian Sipula; John J Dube; Donald K Scott; Robert M O'Doherty Journal: Diabetes Date: 2009-11-23 Impact factor: 9.461